To profile the key players and comprehensively analyze their market shares and core competencies To track and analyze competitive developments such as product launches; agreements, partnerships, and collaborations; mergers & acquisitions; and R&D activities in the NGS-based RNA-Seq market
The global NGS-based RNA-seq market is projected to reach USD 2.65 billion by 2022 from USD 1.05 billion in 2017, at a CAGR of 20.2%.
Factors such as the advantages of RNA-seq over micro array technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the NGS-based RNA-seq market. On the other hand, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market.
In 2016, the sequencing platforms and consumables segment is expected to account for the largest share of the market.The data analysis, storage, and management is expected to register the highest growth rate owing to its development of more efficient data analysis solutions and growing computational capabilities of data analytics providers.
Research centers and academic & government institutes segment accounted for the largest share of the global market in 2016 due to the increasing focus of market players on providing efficient RNA-seq products & services for research applications and the growing number of government funding programs. However, the hospitals and clinics segment is expected to register the highest growth due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics.
Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-seq market owing to the technological advantages of expression profiling applications.
*Top 25 Companies Analyzed for This Study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Pacific Biosciences of California, Inc.
(U.S.), Oxford Nanopore Technologies (U.K.), Perkinelmer, Inc. , (U.S.), Qaigen N.V. (Germany), F.
Hoffmann-La Roche AG (Switzerland), Agilent Technologies (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Gatc Biotech AG (Germany), Macrogen, Inc.
(South Korea), Eurofins Scientific (Luxembourg), BGI (China), Takara Holdings Inc. (Japan), Cofactor Genomics, Inc.
(U.S.), Otogenetics Corporation (U.S.), Nugen Technologies Inc. (U.S.), Hamilton Company (U.S.), Intrexon Corp.
(U.S.), 10x Genomics, Inc. (U.S.), Personalis Inc. (U.S.), Genewiz, Inc. (U.S.), Medgenome Inc.
(U.S.), Novogene Corporation (China), and Biomatters Ltd. (New Zealand)
- NGS equipment manufacturers, vendors, and distributors
- NGS sequencing services companies
- NGS bioinformatics/data analysis companies
- Research institutes and government organizations
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and medical schools)
- Pharmaceutical and biotechnology companies
- Contract manufacturing organizations (CMOS)
- Contract research organizations (CROS)
Key point from table of content
6 Global NGS-based RNA Sequencing Market, By Product & Service
6.1.1 Sample Preparation
184.108.40.206 Sample Preparation, By Workflow Step
7 Global NGS-based RNA Sequencing Market, By Technology
7.2 Sequencing By Synthesis
7.3 Ion Semiconductor Sequencing
7.4 Single-Molecule Real-Time Sequencing
8 Global NGS-based RNA Sequencing Market, By Application
8.2 Expression Profiling Analysis
8.3 Small RNA Sequencing
8.4 De Novo Transcriptome Assembly
8.5 Variant Calling and Transcriptome Epigenetics
9 Global NGS-based RNA Sequencing Market, By End User
9.2 Research Centers and Academic & Government Institutes
9.3 Hospitals & Clinics
9.4 Pharmaceutical & Biotechnology Companies
9.5 Other End Users
Browse Here for full Report with TOC: www.reportsnreports.com/reports/10…-st-to-2022.html